• Vaccine Name: Measles Virus vaccine VEE/SIN-H
• Target Pathogen: Measles virus
• Target Disease: Measles
• Vaccine Ontology ID: VO_0004187
• Type: Recombinant vector vaccine
• Status: Licensed
• H hemagglutinin protein gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intradermal injection (i.d.)

Monkey Response

• Host Strain: Rhesus macaques
• Vaccination Protocol: Juvenile rhesus macaques were vaccinated with a single intradermal (i.d.) injection of 10^8 VEE/SIN-H particles or 108 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles (VEE/SIN-H+F). Two juvenile monkeys were vaccinated with one dose of 5,000 PFU of the Moraten strain of LAV intramuscularly (i.m.). Two juvenile monkeys were vaccinated with three doses of 0.5 ml of FIMV i.m. at 0, 4, and 8 weeks. Three infant rhesus macaques were immunized i.d. with 10^8 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles and boosted 2 months later (Pan et al., 2010)
• Challenge Protocol: For MV challenge, 10^4 tissue culture 50% infectious doses (TCID50) of the Bilthoven strain of MV were instilled intratracheally into anesthetized animals 12 to 17 months after vaccination. Monkeys were shaved and monitored frequently for development of a rash (Pan et al., 2010).
• Efficacy: Neutralizing antibody remained above the protective level for more than 1 year after vaccination with VEE/SIN-H, VEE/SIN-H+F, or LAV. When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia, while FIMV-vaccinated monkeys were not (Pan et al., 2010).